Gilead Sciences, Inc. (GILD) Earns “Buy” Rating from Jefferies Group LLC
Jefferies Group LLC reissued their buy rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note released on Wednesday. Jefferies Group LLC currently has a $63.00 price target on the biopharmaceutical company’s stock.
Several other brokerages have also recently issued reports on GILD. Vetr cut shares of Gilead Sciences from a strong-buy rating to a buy rating and set a $84.73 target price for the company. in a report on Wednesday, January 4th. Leerink Swann restated a market perform rating and issued a $89.00 target price on shares of Gilead Sciences in a report on Tuesday, November 15th. Cowen and Company restated a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Friday, January 6th. Stifel Nicolaus restated a buy rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Wednesday, January 11th. Finally, Robert W. Baird restated an outperform rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Wednesday, December 21st. One research analyst has rated the stock with a sell rating, ten have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $83.19.
Gilead Sciences (NASDAQ:GILD) traded up 0.460% during mid-day trading on Wednesday, reaching $68.855. 19,306,289 shares of the company traded hands. The stock’s 50 day moving average price is $69.70 and its 200 day moving average price is $73.79. The firm has a market capitalization of $90.00 billion, a price-to-earnings ratio of 6.927 and a beta of 1.11. Gilead Sciences has a 52 week low of $65.38 and a 52 week high of $103.10.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.61 by $0.09. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The business earned $7.30 billion during the quarter, compared to analysts’ expectations of $7.16 billion. During the same quarter in the prior year, the business posted $3.32 EPS. The company’s revenue for the quarter was down 13.9% on a year-over-year basis. Equities analysts forecast that Gilead Sciences will post $8.24 EPS for the current year.
Your IP Address:
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 3.01%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date is Tuesday, March 14th. Gilead Sciences’s dividend payout ratio is presently 18.91%.
In related news, insider John C. Martin sold 73,337 shares of the stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the sale, the insider now directly owns 3,204,433 shares of the company’s stock, valued at approximately $235,814,224.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. State of New Jersey Common Pension Fund D boosted its stake in Gilead Sciences by 4.6% in the third quarter. State of New Jersey Common Pension Fund D now owns 2,260,000 shares of the biopharmaceutical company’s stock valued at $178,811,000 after buying an additional 100,000 shares in the last quarter. BB&T Securities LLC boosted its stake in Gilead Sciences by 17.4% in the third quarter. BB&T Securities LLC now owns 718,792 shares of the biopharmaceutical company’s stock valued at $56,870,000 after buying an additional 106,530 shares in the last quarter. Page Arthur B boosted its stake in Gilead Sciences by 37.0% in the third quarter. Page Arthur B now owns 12,640 shares of the biopharmaceutical company’s stock valued at $1,001,000 after buying an additional 3,415 shares in the last quarter. TMD & Associates Inc. boosted its stake in Gilead Sciences by 14.2% in the third quarter. TMD & Associates Inc. now owns 51,919 shares of the biopharmaceutical company’s stock valued at $4,108,000 after buying an additional 6,473 shares in the last quarter. Finally, Seatown Holdings Pte. Ltd. purchased a new stake in Gilead Sciences during the third quarter valued at about $5,111,000. 74.19% of the stock is currently owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.